Rituxan/Mabthera to Maintain the Top Position in Cancer mAbs Created by rncos on 3/21/2012 2:20:04 AM

RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.

As per RNCOS’s new research report entitled “Cancer Monoclonal Antibodies Market to 2015”, cancer represents the fastest growing and one of the most attractive therapeutic segments in the global pharmaceutical market. Among the several drug classes for cancer treatment, antineoplastics mAbs are the leading ones. Key factors, such as fast increase in the number of new cancer cases and the emergence of innovative technologies led to create a US$ 21 Billion worldwide market for antineoplastic mAbs in 2011. Fuelled by ever-increasing cancer cases globally, the market for the same is portraying an optimistic future outlook, worth17 Million by the end of 2020.

Our research report has found that four drugs currently dominate the global antineoplastics mAbs market, including Roche’s Avastin (bevacizumab), MabThera (rituximab), and Herceptin (trastuzumab); and BMS/Merck’s Erbitux. Rituximab is known as Rituxan in the US, Japan, and Canada, and MabThera in Europe. Drug’s sales are likely to have increased by around 7% and reached a market worth US$ 6.8 Billion by the end of 2011. Though in the coming future, Rituxan will face a threat from the entry of bio-similar versions, it is likely to maintain its dominance as the market-leading agent and is anticipated to advance at a CAGR of 5.4% during 2012-2015.

The report investigates and analyzes all the key developments of cancer mAbs’ market throughout the world. It also identifies the possible growth areas in terms of pipeline products and provides an in-depth analysis on the leading drugs under development with reference to their manufacturers and other key details. It also covers an exhaustive research on the country-level cancer mAbs market and offers a broad overview of the current developments.

The report, which is an outcome of prudent analysis and extensive research on the antineoplastic mAbs market, is spread in over 100 pages. It also provides future forecasts for the overall industry and key sections/areas on the basis of past trends, challenges, opportunities for expansion and economic and judgmental analysis. Further, the report illustrates about the approved mAbs, along with their recent industry developments to provide a balanced outlook on the potentials of the growing market.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM375.htm

Yes and No.The server can be cugifnored to ignore “superfluous tags” for phrases. In fact, by default we ignore many common HTML ones like the bold tag.So for a document with:<b>hello</b>worldYou can search for “hello world” and MarkLogic would find the document. We call this feature phrase-through.However, the behavior of the server is such that these tags act as word boundaries. Hence, tags through a word actually break the word into two:<b>super</b>badSearch for “superbad” would miss. Search for “super bad” would hit.I’d call this capability word-through, though we don't currently support it.

UDENT is an Internet-based social dental portal and directory that connects dental professionals, students, and consumers to the world of dental information, tools, and services. UDENT combine the latest in technology and health resources to bring dental professionals, dental students, and consumers to a new era of communication.